)
Anjali Singh covers the automobile and pharmaceutical sectors, focusing on trends, policy developments, regulatory changes, industry expectations, corporate results among others. A postgraduate in communication journalism, she has a strong inclination towards data-driven reporting and enjoys breaking down complex topics to make them interesting and relevant for readers.
Anjali Singh covers the automobile and pharmaceutical sectors, focusing on trends, policy developments, regulatory changes, industry expectations, corporate results among others. A postgraduate in communication journalism, she has a strong inclination towards data-driven reporting and enjoys breaking down complex topics to make them interesting and relevant for readers.
As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics
EV maker reallocates ₹575 crore from R&D to debt repayment and growth as sales slow, market share slips and fundraising challenges persist
Automaker to raise prices across ICE passenger vehicles by 0.5% from April 1, citing sustained rise in input costs; impact will vary across models and variants
Lilly positions tirzepatide as a clinically superior option as semaglutide patent expiry triggers a wave of generics, intensifying competition in India's diabetes and obesity market
Novo Nordisk says competition in semaglutide will be driven by science and quality, not pricing, as multiple generic versions prepare to enter India after patent expiry
Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity
With the war showing no signs of abating, the outlook for many sectors of India's industry is clouding over right now
Ferrari unveiled the 849 Testarossa in India, signalling a deeper push into the fast-growing luxury car market as rising wealth and a new generation of collectors fuel demand
Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation
Tata Motors has secured cumulative orders for over 5,000 buses and chassis from multiple state transport undertakings through government e-bidding, reinforcing its presence in public transport
Acquisition of automotive utility app Vehicle Info will help CARS24 expand beyond buying and selling vehicles to build a platform offering services across the entire ownership lifecycle
Tyre makers warn that the West Asia conflict may disrupt exports, raise crude-linked input costs and strain supply chains, prompting ATMA to seek urgent policy support
LPG and natural gas shortages are beginning to disrupt parts of Indian industry, though most sectors say production remains largely stable for now
India and Uzbekistan have launched a policy-backed pharma-nutraceutical corridor to improve regulatory alignment, investment and market access for manufacturers targeting the $7-10 billion Eurasian he
Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work
Motilal Oswal Financial Services has purchased a 1.65 per cent stake in Zelio E-Mobility through a Rs 9.8 crore block deal, boosting institutional interest in the newly listed EV maker
Mahindra said it has received no intimation from Indonesian authorities about suspending its vehicle imports, clarifying a media report and reaffirming its 35,000-unit export order
Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio
Mercedes-Benz has localised assembly of V-Class in India, bringing its entry price to ₹1.4 cr, reducing dependence on costly imports, as the company repositions the van within its top-end portfolio
Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand